Iceland - July 18, 2023
Controlant opens a new office in Denmark
The company’s presence in Copenhagen positions Controlant to tap into Denmark’s strong life-science ecosystem, get closer to its customers, access a large pool of skilled professionals, and more closely collaborate with technology and industry partners, it states. Controlant is on a growth journey driven. With over 430 people from more than 40 different countries, the […]
Biotech Business - May 30, 2023
Oculis listed on Nasdaq in New York
The Iceland-founded biopharmaceutical company was officially listed on the Nasdaq stock exchange in New York, making it the first Icelandic VC portfolio company to go public. Both Klappir and Solid Clouds were previously listed on the Nasdaq First North Growth Market in Iceland, but neither counted Icelandic VC’s as investors when going public. The same […]
Business - January 18, 2023
A hotbed for innovation and technology
The new science city in Reykjavik is set to attract growing companies, foreign investors and even more talent. Despite being one of the world’s smallest capitals, Reykjavik has an innovative and creative atmosphere, not least within life sciences. The life science industry includes biotech, pharma, genetics, and medical devices, and it is a growing sector […]
Iceland - November 9, 2022
Advanced visibility for the life science supply chain
Controlant’s real-time supply chain monitoring and visibility technologies are specifically geared to the pharmaceutical and life sciences sectors and emerged as a key cold chain solution for the COVID-19 vaccines during the pandemic. The COVID-19 pandemic has really shed light on the importance of a robust, efficient, quick, sustainable and cost-effective pharma supply chain. In […]
Iceland - November 2, 2022
New multiomics study of nonalcoholic fatty liver disease
Scientists at deCODE genetics in Iceland have discovered rare, protective loss-of-function variants that point to potential drug targets for nonalcoholic fatty liver disease (NAFLD). Last week, the scientists published a large genome-wide association study on nonalcoholic fatty liver disease (NAFLD) in Nature Genetics. Sequence variants that associate with NAFLD were identified, including rare, protective loss-of-function […]
Clinical Trials - September 2, 2022
EpiEndo starts clinical trial with its lead molecule
EpiEndo Pharmaceuticals has received regulatory and ethics approval to commence a Lipopolysaccharide (LPS) challenge clinical trial with its lead molecule EP395. EP395 is an orally available macrolide or ‘Barriolide’ with reduced antimicrobial activity which aims to address the unmet medical need for a treatment for COPD (Chronic Obstructive Pulmonary Disease). “Commencing this study is the […]
